Press coverage about Endologix (NASDAQ:ELGX) has been trending somewhat positive on Tuesday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Endologix earned a coverage optimism score of 0.22 on Accern’s scale. Accern also gave news coverage about the medical instruments supplier an impact score of 45.8218686683697 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Recommendation Hold on stock: Endologix, Inc. (ELGX) – Street Observer (press release) (streetobserver.com)
- Endologix (ELGX) Reports Collaboration Agreements with Japan Lifeline for Development & Commercialization of … – StreetInsider.com (streetinsider.com)
- ENDOLOGIX : Announces Collaboration Agreements with Japan Lifeline for the Development and Commercialization of Thoracic Endovascular Systems in Japan (4-traders.com)
- Endologix Announces Collaboration Agreements with Japan Lifeline for the Development and Commercialization of Thoracic Endovascular Systems in Japan (finance.yahoo.com)
- Government Properties Income Tr (NASDAQ:GOV) Sees Significantly Lower Trading Volume (topactu.net)
Endologix (ELGX) traded down 3.74% on Tuesday, reaching $4.37. 518,836 shares of the company traded hands. Endologix has a one year low of $4.08 and a one year high of $13.30. The firm has a 50 day moving average of $4.47 and a 200-day moving average of $5.61. The stock’s market capitalization is $364.61 million.
Endologix (NASDAQ:ELGX) last released its earnings results on Wednesday, August 2nd. The medical instruments supplier reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.08. The business had revenue of $48.60 million during the quarter, compared to the consensus estimate of $47.58 million. Endologix had a negative net margin of 40.77% and a negative return on equity of 46.32%. The company’s revenue for the quarter was down 4.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.20) EPS. On average, analysts anticipate that Endologix will post ($0.62) EPS for the current year.
Several research analysts have recently issued reports on the stock. Stifel Nicolaus reaffirmed a “buy” rating and issued a $5.50 target price (up previously from $5.00) on shares of Endologix in a research note on Monday, June 5th. Stephens lowered shares of Endologix from an “overweight” rating to an “equal weight” rating and set a $6.00 target price on the stock. in a research note on Thursday, May 18th. Oppenheimer Holdings, Inc. set a $5.00 target price on shares of Endologix and gave the company a “hold” rating in a research note on Thursday, August 3rd. Royal Bank Of Canada reaffirmed a “hold” rating and issued a $5.00 target price on shares of Endologix in a research note on Monday, July 31st. Finally, Zacks Investment Research lowered shares of Endologix from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 25th. Two analysts have rated the stock with a sell rating and eleven have assigned a hold rating to the stock. Endologix presently has an average rating of “Hold” and an average price target of $6.28.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.